Serum markers of inflammation and oxidative stress in chronic opium (Taryak) smokers

Immunology Letters

Volumn 153, Issue 1-2, 2013, Pages 22-26

  Ghazavi, Ali ^a   Mosayebi, Ghasem ^b   Solhi, Hassan ^c   Rafiei, Mohammad ^c   Moazzeni, Seyed Mohammad ^a  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b ARAK UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ARAK UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Complement factors; Hs CRP; Nitric oxide; Opium smokers; Total antioxidant capacity

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; IMMUNOGLOBULIN A; IMMUNOGLOBULIN M; NITRIC OXIDE; OPIATE;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPLEMENT BLOOD LEVEL; CONTROLLED STUDY; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INFLAMMATION; MALE; OPIATE ADDICTION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

COMPLEMENT FACTORS; HS-CRP; NITRIC OXIDE; OPIUM SMOKERS; TOTAL ANTIOXIDANT CAPACITY;

ADULT; ANTIOXIDANTS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; COMPLEMENT C3; COMPLEMENT C4; HUMANS; IMMUNOGLOBULINS; INFLAMMATION; MALE; NITRIC OXIDE; OPIUM; OXIDATIVE STRESS; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

EID: 84880979608     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2013.07.001     Document Type: Article

References (40)

1. Rajabizade G., Ramezani M.A., Shakibi M.R. Prevalence of opium addiction in Iranian drivers 2001-2003. J Med Sci 2004, 4:210-213.
2. Shiri R., Hassani K.F., Ansari M. Association between opium abuse and comorbidity in diabetic men. Am J Addict 2006, 15:468-472.
3. Bourgeois M.M., Richards I.S. Gender-specific differences in the urinary expression of aldosterone, IL-1α and IL-1β. Biomarkers 2010, 4:843-847.
4. Nasrollahzadeh D., Kamangar F., Aghcheli K., Sotoudeh M., Islami F., Abnet C., et al. Opium, tobacco, and alcohol use in relation to oesophageal squamous cell carcinoma in a high-risk area of Iran. Br J Cancer 2008, 98:1857-1863.
5. Rebrova T.Y., Maslov L.N., Lishmanov A.Y., Tam S.V. Stimulation of mu and delta-opiate receptors and tolerance of isolated heart to oxidative stress: the role of NO-synthase. Biochemistry (Mosc) 2001, 66:422-428.
6. Sadeghian S., Graili P., Salarifar M., Karimi A.A., Darvish S., Abbasi S.H. Opium consumption in men and diabetes mellitus in women are the most important risk factors of premature coronary artery disease in Iran. Int J Cardiol 2010, 141:116-118.
7. Yang Y., Karakhanova S., Soltek S., Werner J., Philippov P.P., Bazhin A.V. In vivo immunoregulatory properties of the novel mitochondria-targeted antioxidant SkQ1. Mol Immunol 2012, 52:19-29.
8. Yang Y., Bazhin A.V., Werner J., Karakhanova S. Reactive oxygen species in the immune system. Int Rev Immunol 2013, 32:249-270.
9. Elgert K.D. Immunology: understanding the immune system 2009, Wiley-Blackwell.
10. Colasanti M., Suzuki H. The dual personality of NO. Trends Pharmacol Sci 2000, 21:249-252.
11. Beckman J.S., Koppenol W.H. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol Cell Physiol 1996, 271. C1424-C37.
12. Grisham M.B., Jourd'Heuil D., Wink D.A.I. Physiological chemistry of nitric oxide and its metabolites: implications in inflammation. Am J Physiol Gastrointest Liver Physiol 1999, 276. G315-G21.
13. Schiff P.L. Opium and its alkaloids. Am J Pharm Educ 2002, 66:188-196.
14. Mosayebi G., Ghazavi A., Mashhadi Z. Association of uric acid and C-reactive protein with severity of preeclampsia in Iranian women. J Med Sci 2008, 8:239-243.
15. Mirshafiey A., Aghily B., Namaki S., Razavi A., Ghazavi A., Ekhtiari P., et al. Therapeutic approach by Aloe vera in experimental model of multiple sclerosis. Immunopharmacol Immunotoxicol 2010, 32:410-415.
16. Sun J., Zhang X., Broderick M., Fein H. Measurement of nitric oxide production in biological systems by using Griess reaction assay. Sensors 2003, 3:276-284.
17. Benzie I.F., Strain J. The ferric reducing ability of plasma (FRAP) as a measure of antioxidant power: the FRAP assay. Anal Biochem 1996, 239:70-76.
18. Mosayebi G., Haghmorad D., Namaki S., Ghazavi A., Ekhtiari P., Mirshafiey A. Therapeutic effect of EDTA in experimental model of multiple sclerosis. Immunopharmacol Immunotoxicol 2010, 32:321-326.
19. Kianbakht S., Ghazavi A. Immunomodulatory effects of saffron: a randomized double-blind placebo-controlled clinical trial. Phytother Res 2011, 25:1801-1805.
20. Karam G.A., Reisi M., Kaseb A.A., Khaksari M., Mohammadi A., Mahmoodi M. Effects of opium addiction on some serum factors in addicts with non-insulin-dependent diabetes mellitus. Addict Biol 2004, 9:53-58.
21. Guo S., Sheng L., Cheng Y., Jiang Z. Changes of immune system of heroin addicts after natural withdrawal. Chin J Drug Depend 2002, 11:269-273.
22. Radenkova-Saeva J., Marinova S., Kostadinova R., Petrunov B. Study of certain changes in humoral immunity and hypersensitivity in heroin addicts with hepatitis C. GODINA 2004, 107. 2004.
23. Asgary S., Sarrafzadegan N., Naderi G.-A., Rozbehani R. Effect of opium addiction on new and traditional cardiovascular risk factors: do duration of addiction and route of administration matter?. Lipids Health Dis 2008, 7:42.
24. Das I. Raised C-reactive protein levels in serum from smokers. Clin Chim Acta 1985, 153:9-13.
25. Kop W.J., Gottdiener J.S., Tangen C.M., Fried L.P., McBurnie M.A., Walston J., et al. Inflammation and coagulation factors in persons >65 years of age with symptoms of depression but without evidence of myocardial ischemia. Am J Cardiol 2002, 89:419-424.
26. Friedman H., Newton C., Klein T.W. Microbial infections, immunomodulation, and drugs of abuse. Clin Microbiol Rev 2003, 16:209-219.
27. Arias J.F., Nishihara R., Bala M., Ikuta K. High systemic levels of interleukin-10, interleukin-22 and C-reactive protein in Indian patients are associated with low in vitro replication of HIV-1 subtype C viruses. Retrovirology 2010, 7:15.
28. Urbanska-Rys H., Wiersbowska A., Stepien H., Robak T. Relationship between circulating interleukin-10 (IL-10) with interleukin-6 (IL-6) type cytokines (IL-6), interleukin-11 (IL-11), oncostatin M (OSM) and soluble interleukin-6 (IL-6) receptor (sIL-6R) in patients with multiple myeloma. Eur Cytokine Netw 2000, 11:443-451.
29. Andersen S.N., Skullerud K. Hypoxic/ischaemic brain damage, especially pallidal lesions, in heroin addicts. Forensic Sci Int 1999, 105:51-59.
30. White A.G. Medical disorders in drug addicts 200 consecutive admissions. J Am Med Assoc 1973, 223:1469-1471.
31. Grieco M.H., Chuang C.Y. Hypermacroglobulinemia associated with heroin use in adolescents. J Allergy Clin Immunol 1973, 51:152-160.
32. Dianxi L. Changes in immunological function and superoxide dismutase levels of sera in heroin addicts. J Guiyang Med Coll 1996, 02.
33. M. El-Fiky, M. Owida, A. Wilson, M. Fahmy, Heroin abusers: an immunological aspect. Curr Psychiat 2, 1994, 166-171.
34. Orangio G., Pitlick S.D., Della Latta P., Mandel L.J., Marino C., Guarneri J.J., et al. Soft tissue infections in parenteral drug abusers. Ann Surg 1984, 199:97.
35. Pratibha N., Murty J., Reddy K. Serum levels of IgA in peptic ulcers. Biochem Med Metab Biol 1987, 37:350-356.
36. Tuteja N., Chandra M., Tuteja R., Misra M.K. Nitric oxide as a unique bioactive signaling messenger in physiology and pathophysiology. BioMed Res Int 2004, 2004:227-237.
37. Lysle D.T., How T. Heroin modulates the expression of inducible nitric oxide synthase. Immunopharmacology 2000, 46:181-192.
38. Pan J., Zhang Q., Zhang Y., Ouyang Z., Zheng Q., Zheng R. Oxidative stress in heroin administered mice and natural antioxidants protection. Life Sci 2005, 77:183-193.
39. Gülçin I., Beydemir Ş., Alici H.A., Elmastaş M., Büyükokuroǧlu M.E. In vitro antioxidant properties of morphine. Pharmacol Res 2004, 49:59-66.
40. Roy S., Ninkovic J., Banerjee S., Charboneau R.G., Das S., Dutta R., et al. Opioid drug abuse and modulation of immune function: consequences in the susceptibility to opportunistic infections. J Neuroimmune Pharmacol 2011, 6:442-465.